391 related articles for article (PubMed ID: 20019837)
1. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
2. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.
Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS
Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136
[TBL] [Abstract][Full Text] [Related]
3. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
[TBL] [Abstract][Full Text] [Related]
4. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.
Yi S; Tsao MS
Neoplasia; 2000; 2(3):226-34. PubMed ID: 10935508
[TBL] [Abstract][Full Text] [Related]
5. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
Shi W; Song J; Wang W; Zhang Y; Zheng S
Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
7. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
[TBL] [Abstract][Full Text] [Related]
8. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
To C; Seiden I; Liu N; Wigle D; Tsao MS
Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
[TBL] [Abstract][Full Text] [Related]
9. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
11. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
[TBL] [Abstract][Full Text] [Related]
12. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
13. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
Stabile LP; Rothstein ME; Gubish CT; Cunningham DE; Lee N; Siegfried JM
J Thorac Oncol; 2014 Sep; 9(9):1285-93. PubMed ID: 25057941
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
16. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
[TBL] [Abstract][Full Text] [Related]
18. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
[TBL] [Abstract][Full Text] [Related]
19. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
[TBL] [Abstract][Full Text] [Related]
20. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
